



(51) International Patent Classification:

C07D 295/192 (2006.01) **A61P 25/18** (2006.01)
A61K 31/495 (2006.01) **A61P 25/28** (2006.01)
A61P 25/00 (2006.01)

(21) International Application Number:

PCT/SE2011/050172

(22) International Filing Date:

17 February 2011 (17.02.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/305,583 18 February 2010 (18.02.2010) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **UCZYNSKI, Michael A.** [US/US]; AstraZeneca R&D Wilmington,

1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).


(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: NEW CRYSTALLINE FORM OF A CYCLOPROPYL BENZAMIDE DERIVATIVE



(57) **Abstract:** The present invention relates to a crystalline form of compound (I), 4-[(1S, 2S)-2-[(4-cyclobutylpiperazin-1-yl)carbonyl]-cyclopropyl]-benzamide, (I) pharmaceutical formulations containing said compound and to the use of said active compound in therapy.





LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, **Published:**
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with international search report (Art. 21(3))*
GW, ML, MR, NE, SN, TD, TG).